Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: A placebo-controlled, double-blind, randomized trial

This publication has 21 references indexed in Scilit:

• Acetylcysteine Reduces Plasma Homocysteine Concentration and Improves Pulse Pressure and Endothelial Function in Patients With End-Stage Renal Failure
  Circulation, 2004
• The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: A randomized, controlled study
  American Journal of Kidney Diseases, 2003
• L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients
  Kidney International, 2001
• Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study
  Atherosclerosis, 1996
• Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
  Atherosclerosis, 1996
• High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
  Kidney International, 1996
• Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study
  Atherosclerosis, 1995
• Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation
  Atherosclerosis, 1995
• Extracorporeal Regional Complexing Haemodialysis Treatment of Acute Inorganic Mercury Intoxication
  Human & Experimental Toxicology, 1990
• TREATMENT OF LEAD POISONING BY 2,3-DIMERCAPTOSUCCINIC ACID
  The Lancet, 1978